MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
8.12
-0.17
-2.05%
After Hours: 8.12 0 0.00% 19:53 09/11 EDT
OPEN
8.30
PREV CLOSE
8.29
HIGH
8.40
LOW
8.11
VOLUME
3.59M
TURNOVER
--
52 WEEK HIGH
11.22
52 WEEK LOW
6.00
MARKET CAP
2.07B
P/E (TTM)
-5.3989
1D
5D
1M
3M
1Y
5Y
1D
Is BioCryst Pharmaceuticals (BCRX) Undervalued After Its Recent Share Price Slide?
Simply Wall St · 11h ago
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity
Seeking Alpha · 1d ago
BioCryst Pharmaceuticals Price Target Cut to $11.00/Share From $13.00 by RBC Capital
Dow Jones · 2d ago
BioCryst Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital
Dow Jones · 2d ago
RBC Capital Downgrades BioCryst Pharma to Sector Perform, Lowers Price Target to $11
Benzinga · 2d ago
BioCryst downgraded to Sector Perform from Outperform at RBC Capital
TipRanks · 2d ago
Ten healthcare stocks with A-rated valuations and strong revenue growth
Seeking Alpha · 3d ago
BioCryst Pharmaceuticals Price Target Maintained With a $16.00/Share by Needham
Dow Jones · 4d ago
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.